Triple therapy before surgery for liver cancer
Part of Cancer clinical trials.
This trial tests whether a combination of three drugs given before surgery can help shrink liver cancer and improve outcomes for patients whose tumors can be removed. It is for people with intermediate-stage liver cancer that is still operable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your liver function is good (Child-Pugh class A).
- Your cancer is stage A or B according to BCLC staging, and your tumor(s) are larger than 5 cm or there are multiple tumors.
- You have not had any prior cancer treatment like surgery, chemotherapy, targeted therapy, or immunotherapy.
- You are willing to use contraception during and for 6 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a combination of three drugs (anti-CTLA-4, anti-PD-1, and bevacizumab) before and after surgery can help people with resectable liver cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This study tests a combination of three treatments (HAIC, camrelizumab, and apatinib) given before and after surgery for early-stage liver cancer that has high risk of coming back. The goal is to reduce the chance of cancer recurrence and improve survival.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
Hear when a new Resectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.